HSIC — Henry Schein, Inc.

Is HSIC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Distribution

Oversold As of October 3, 2026

Henry Schein, Inc. (HSIC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Distribution) last closed at $84.88. The rating moved from Strong Oversold to Oversold on September 24, 2026.

See all oversold Healthcare stocks →

AI analysis

Henry Schein benefits from a defensible distribution franchise in dental and medical consumables, a growing services/software mix, and steady cash generation that together support moderate upside. Near-term direction is likely to track broader risk-off market sentiment and elective procedure activity; key upside catalysts include continued software adoption, equipment cycle recovery, and successful M&A integration. Main vulnerabilities are demand cyclicality for elective care, supply-chain disruption, competitive pricing pressure, and execution on higher-margin initiatives.

Key factors

  • Diversified distribution model with recurring consumables revenue from dental and medical practices, providing stable cash flow and predictable demand.
  • Leading market position in dental supplies and equipment with scale advantages versus regional competitors, enabling favorable vendor terms and broad customer reach.
  • Growth in higher-margin software, services and equipment businesses (practice management, imaging, digital workflow) improves revenue mix over time and supports margin expansion.
  • Post-pandemic normalization of elective dental procedures and practice reopenings continues to underpin demand for consumables and equipment replacement cycles.
  • Prudent balance-sheet management and historically steady free cash flow generation support dividends, buybacks and selective M&A to consolidate the sector.

Risks

  • Demand sensitivity to macroeconomic weakness or consumer cost pressures that reduce elective dental visits and discretionary equipment spending.
  • Supply-chain disruptions or inventory constraints that inflate costs or create fulfillment delays for customers.
  • Competitive pressure from other distributors and vertical integrators (pricing pressure or share loss), including regional distributors and e-commerce entrants.
  • Execution risk on integration of acquisitions and scaling higher-growth software/services offerings; slower-than-expected margin improvement would pressure valuation.
  • Regulatory/reimbursement changes or broader healthcare policy shifts that indirectly affect customer economics or product pricing dynamics.
  • Foreign exchange exposure and international market volatility that could compress reported results given global footprint.

See today's live rating, score and targets

Members see the live hourly rating for HSIC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.